🇺🇸 FDA
Company

Prelude

Prelude Therapeutics Inc

PRLD pharma USA

Quick answer

Prelude is a pharma company (PRLD) headquartered in WILMINGTON, DE, USA with 11 tracked pipeline programs.

Pipeline (11)

project

PRT3789

Advanced Solid Tumor

Phase 2 · small_molecule · completed

2 trials project

PRT12396

Polycythemia Vera (PV)

Phase 1 · small_molecule · active

1 trials project

PRT1419

Multiple Myeloma

Phase 1 · small_molecule · completed

1 trials project

PRT1419

Sarcoma

Phase 1 · small_molecule · completed

1 trials project

PRT1419

Acute Myeloid Leukemia

Phase 1 · small_molecule · terminated

1 trials project

PRT2527

Sarcoma

Phase 1 · small_molecule · completed

1 trials project

PRT2527

Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1 · small_molecule · completed

1 trials project

PRT3645

Breast Cancer

Phase 1 · small_molecule · completed

1 trials project

PRT543

Relapsed/Refractory Advanced Solid Tumors

Phase 1 · small_molecule · completed

1 trials project

PRT7732

Advanced Solid Tumor

Phase 1 · small_molecule · terminated

1 trials project

PRT811

Advanced Solid Tumor

Phase 1 · small_molecule · completed

1 trials

Patents (8)

patent

US 12414953

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12129262

CDK inhibitors and their use as pharmaceuticals

Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11939340

CDK inhibitors and their use as pharmaceuticals

Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11702423

BRM targeting compounds and associated methods of use

Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11685744

CDK inhibitors and their use as pharmaceuticals

Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11673893

CDK inhibitors and their use as pharmaceuticals

Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11622970

BCL-2 inhibitors and their use as pharmaceuticals

Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11524962

Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl t

Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)